A Multi-center, Multinational, Noninterventional Study With Certolizumab Pegol in Comparison to Any Other Subcutaneous TNF Inhibitor in Two Parallel Groups in Biologic Naive Patients With Rheumatoid Arthritis

Trial Profile

A Multi-center, Multinational, Noninterventional Study With Certolizumab Pegol in Comparison to Any Other Subcutaneous TNF Inhibitor in Two Parallel Groups in Biologic Naive Patients With Rheumatoid Arthritis

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Jul 2018

At a glance

  • Drugs Certolizumab pegol (Primary) ; Adalimumab; Disease-modifying antirheumatics; Etanercept; Golimumab
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms NexT
  • Sponsors UCB Pharma SA
  • Most Recent Events

    • 28 Jun 2018 Status changed from recruiting to active, no longer recruiting.
    • 18 Aug 2017 Planned number of patients changed from 1360 to 1700.
    • 18 Aug 2017 Planned End Date changed from 1 Mar 2020 to 23 Oct 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top